VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Abstract Text:

Dan G Duda,Tracy T Batchelor,Christopher G Willett,Rakesh K Jain,Dan G Duda,Tracy T Batchelor,Christopher G Willett,Rakesh K Jain,

Despite setbacks, the clinical development of antiangiogenic agents has accelerated remarkably over the past 3-4 years. Consequently, there are currently three direct inhibitors of the VEGF pathway approved for use in cancer therapy. Other agents that block the VEGF pathway are in advanced stages of clinical development and have shown promising results. With these exciting developments come crucial questions regarding the use of these new molecular-targeted agents, alone or in combination with standard cytotoxic or targeted agents. Importantly, the mechanisms of action of anti-VEGF therapy remain unknown. Here, we discuss several potential mechanisms of action such as tumor vascular normalization, bone marrow-derived cell recruitment blockade and cytostatic effects of anti-VEGF therapy. We review the current progress, the major stumbling blocks and the future directions for anti-cancer therapy using anti-VEGF agents, emphasizing clarification of the underlying molecular mechanisms of action and biomarker identification and validation.

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Publishing Authors By Initials

DG Duda,TT Batchelor,CG Willett,RK Jain,DG Duda,TT Batchelor,CG Willett,RK Jain,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Trends in molecular medicine

VOLUME: 13

Page Numbers: 223-30

Journal Abbreviation:

ISSN: 1471-4914

DAY: 25

MONTH: 04

YEAR: 2007

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100966035

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.

AFFILIATION: Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox-734, Boston, MA 02114, USA.

Country: England

AGENCY: United States NCI

GRANT: R21-CA117079

ACRONYM: CA

MEDLINETA: Trends Mol Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects Related Publications

• A comparison of three methods of recovery of goat oocytes for in vitro maturation and feritilization.
• A novel high throughput quantum dot-based fluorescence assay for quantitation of virus binding and attachment.
• A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.
• Ainsliaea latifolia: An Adulterant of Indian Podophyllum.
• Application of quantum dots to multicolor microarray experiments: four-color genotyping.
• Applied neurogenomics.
• Bronchoalveolar lavage fluid from patients with acute lung injury/acute respiratory distress syndrome induces myofibroblast differentiation.
• Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
• Dendritic cells in autoimmune diseases and neuroinflammatory disorders.
• Dermoid of the conus medullaris.
• Evidence of linkage and association on 18p11.2 for psychosis.
• Functional defects in transfer RNAs lead to the accumulation of ribosomal RNA precursors.
• Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications.
• Induction of pro-inflammatory cytokines by human T-cell leukemia virus type-1 Tax protein as determined by multiplexed cytokine protein array analyses of human dendritic cells.
• Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers.
• Kruppel-like factor 4 regulates endothelial inflammation.
• Muscular dystrophies and related skeletal muscle disorders in an Indian population--a prospective correlative study.
• Neurofibromatosis type I presenting with urinary retention and lung collapse.
• Oxidative stress and metabolic diseases: Introduction.
• Plasma and urine levels of resistin and adiponectin in chronic kidney disease.
• Regulation of gluconeogenesis by Krüppel-like factor 15.
• Scoring functions for protein-ligand docking.
• Spectrophotometric assays of diloxanide furoate and tinidazole in combined dosage forms.
• Superior mesenteric artery syndrome.
• Superoxide dismutase overexpression and cellular oxidative damage in diabetes. A commentary on "Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress".
• Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search.
• Synthesis and evaluation of N-acetyl-L-tyrosine based compounds as PPARalpha selective activators.
• Synthesis, antimalarial, antileishmanial, antimicrobial, cytotoxicity, and methemoglobin (MetHB) formation activities of new 8-quinolinamines.
• The clinical pattern and complications of severe malaria in the Gizan region of Saudi Arabia.
• Vitamin B6 (pyridoxamine) supplementation and complications of diabetes.